Proteome of Renal Tubuli and Serum Differentiate Pre-Existing Type 2 Diabetes and Post-Transplant Diabetes in Kidney Transplant Recipients.

IF 2.1 4区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
PROTEOMICS – Clinical Applications Pub Date : 2025-05-01 Epub Date: 2025-02-24 DOI:10.1002/prca.70000
Eleni Skandalou, Mariell Rivedal, Hans-Peter Marti, Thea A S Halden, Trond Jenssen, Bjørn Egil Vikse, Anders Åsberg, Jessica Furriol
{"title":"Proteome of Renal Tubuli and Serum Differentiate Pre-Existing Type 2 Diabetes and Post-Transplant Diabetes in Kidney Transplant Recipients.","authors":"Eleni Skandalou, Mariell Rivedal, Hans-Peter Marti, Thea A S Halden, Trond Jenssen, Bjørn Egil Vikse, Anders Åsberg, Jessica Furriol","doi":"10.1002/prca.70000","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Diabetes mellitus (DM) is a major cause of end-stage kidney disease (ESKD), with kidney transplantation being the preferred treatment. However, post-transplant diabetes mellitus (PTDM) increases mortality and graft loss. While PTDM and Type 2 diabetes mellitus (T2DM) share risk factors, their mechanisms differ, particularly in diabetic nephropathy (DN). This study aimed to investigate the molecular differences in PTDM by mapping the proteomes of proximal tubuli and serum in normoglycemic (NG), pre-transplant T2DM, and PTDM patients one year post-transplantation. Experimental Design Proteomic analysis was performed on microdissected proximal tubular cells and serum samples from kidney transplant recipients categorized as NG, pre-transplant T2DM, or PTDM at one year post-transplantation. Mass spectrometry was used to identify differentially expressed proteins. Data analyses were performed using gene ontology databases and pathway analysis.</p><p><strong>Results: </strong>Proteomic analysis revealed key differences, including significant dysregulation of mitochondrial proteins and lipid metabolism pathways in PTDM patients compared to T2DM and NG groups. Additionally, we observed distinct serum patterns of cholesterol metabolism dysregulation in PTDM, highlighting a complex interplay between fatty acid metabolism, mitochondrial dysfunction and systemic lipid dysregulation that may drive renal injury in PTDM-related DN.</p><p><strong>Conclusions and clinical relevance: </strong>This pilot study is the first to perform proteomic analysis on both microdissected tubular cells and serum from post-transplant PTDM, pre-transplant T2DM and NG transplant recipients. The proteomic differences between PTDM and T2DM could help to develop targeted therapies and early diagnostic markers, ultimately improving transplant outcomes and patient management. Further research is needed to validate these findings and explore their therapeutic potential.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e70000"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069002/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.70000","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Diabetes mellitus (DM) is a major cause of end-stage kidney disease (ESKD), with kidney transplantation being the preferred treatment. However, post-transplant diabetes mellitus (PTDM) increases mortality and graft loss. While PTDM and Type 2 diabetes mellitus (T2DM) share risk factors, their mechanisms differ, particularly in diabetic nephropathy (DN). This study aimed to investigate the molecular differences in PTDM by mapping the proteomes of proximal tubuli and serum in normoglycemic (NG), pre-transplant T2DM, and PTDM patients one year post-transplantation. Experimental Design Proteomic analysis was performed on microdissected proximal tubular cells and serum samples from kidney transplant recipients categorized as NG, pre-transplant T2DM, or PTDM at one year post-transplantation. Mass spectrometry was used to identify differentially expressed proteins. Data analyses were performed using gene ontology databases and pathway analysis.

Results: Proteomic analysis revealed key differences, including significant dysregulation of mitochondrial proteins and lipid metabolism pathways in PTDM patients compared to T2DM and NG groups. Additionally, we observed distinct serum patterns of cholesterol metabolism dysregulation in PTDM, highlighting a complex interplay between fatty acid metabolism, mitochondrial dysfunction and systemic lipid dysregulation that may drive renal injury in PTDM-related DN.

Conclusions and clinical relevance: This pilot study is the first to perform proteomic analysis on both microdissected tubular cells and serum from post-transplant PTDM, pre-transplant T2DM and NG transplant recipients. The proteomic differences between PTDM and T2DM could help to develop targeted therapies and early diagnostic markers, ultimately improving transplant outcomes and patient management. Further research is needed to validate these findings and explore their therapeutic potential.

肾移植受者肾小管蛋白质组和血清区分既往2型糖尿病和移植后糖尿病
目的:糖尿病(DM)是终末期肾脏疾病(ESKD)的主要原因,肾移植是首选的治疗方法。然而,移植后糖尿病(PTDM)增加死亡率和移植物损失。虽然PTDM和2型糖尿病(T2DM)有共同的危险因素,但它们的机制不同,特别是在糖尿病肾病(DN)中。本研究旨在通过绘制正常血糖(NG)、移植前T2DM和移植后1年PTDM患者近端小管和血清的蛋白质组来研究PTDM的分子差异。研究人员对肾移植受者的近端小管细胞和血清样本进行了蛋白质组学分析,这些肾移植受者在移植后一年被分类为NG、移植前T2DM或PTDM。质谱法鉴定差异表达蛋白。数据分析采用基因本体数据库和通路分析。结果:与T2DM和NG组相比,蛋白质组学分析揭示了关键差异,包括PTDM患者线粒体蛋白和脂质代谢途径的显著失调。此外,我们观察到PTDM患者胆固醇代谢失调的不同血清模式,强调脂肪酸代谢、线粒体功能障碍和全身脂质失调之间的复杂相互作用可能导致PTDM相关DN的肾脏损伤。结论和临床意义:这项初步研究首次对移植后PTDM、移植前T2DM和NG移植受者的微解剖小管细胞和血清进行蛋白质组学分析。PTDM和T2DM之间的蛋白质组学差异有助于开发靶向治疗和早期诊断标记,最终改善移植结果和患者管理。需要进一步的研究来验证这些发现并探索其治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PROTEOMICS – Clinical Applications
PROTEOMICS – Clinical Applications 医学-生化研究方法
CiteScore
5.20
自引率
5.00%
发文量
50
审稿时长
1 months
期刊介绍: PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信